These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1015 related articles for article (PubMed ID: 35750137)

  • 1. Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease - novel insights into cellular communication circuits.
    Peiseler M; Schwabe R; Hampe J; Kubes P; Heikenwälder M; Tacke F
    J Hepatol; 2022 Oct; 77(4):1136-1160. PubMed ID: 35750137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nuclear Receptors Linking Metabolism, Inflammation, and Fibrosis in Nonalcoholic Fatty Liver Disease.
    Puengel T; Liu H; Guillot A; Heymann F; Tacke F; Peiseler M
    Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH.
    Tacke F; Puengel T; Loomba R; Friedman SL
    J Hepatol; 2023 Aug; 79(2):552-566. PubMed ID: 37061196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intestinal B cells license metabolic T-cell activation in NASH microbiota/antigen-independently and contribute to fibrosis by IgA-FcR signalling.
    Kotsiliti E; Leone V; Schuehle S; Govaere O; Li H; Wolf MJ; Horvatic H; Bierwirth S; Hundertmark J; Inverso D; Zizmare L; Sarusi-Portuguez A; Gupta R; O'Connor T; Giannou AD; Shiri AM; Schlesinger Y; Beccaria MG; Rennert C; Pfister D; Öllinger R; Gadjalova I; Ramadori P; Rahbari M; Rahbari N; Healy ME; Fernández-Vaquero M; Yahoo N; Janzen J; Singh I; Fan C; Liu X; Rau M; Feuchtenberger M; Schwaneck E; Wallace SJ; Cockell S; Wilson-Kanamori J; Ramachandran P; Kho C; Kendall TJ; Leblond AL; Keppler SJ; Bielecki P; Steiger K; Hofmann M; Rippe K; Zitzelsberger H; Weber A; Malek N; Luedde T; Vucur M; Augustin HG; Flavell R; Parnas O; Rad R; Pabst O; Henderson NC; Huber S; Macpherson A; Knolle P; Claassen M; Geier A; Trautwein C; Unger K; Elinav E; Waisman A; Abdullah Z; Haller D; Tacke F; Anstee QM; Heikenwalder M
    J Hepatol; 2023 Aug; 79(2):296-313. PubMed ID: 37224925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peroxisome Proliferator-Activated Receptors and Their Novel Ligands as Candidates for the Treatment of Non-Alcoholic Fatty Liver Disease.
    Fougerat A; Montagner A; Loiseau N; Guillou H; Wahli W
    Cells; 2020 Jul; 9(7):. PubMed ID: 32650421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of xenobiotic nuclear receptors in high-fat diet induced non-alcoholic fatty liver disease.
    Li X; Wang Z; Klaunig JE
    Toxicology; 2018 Dec; 410():199-213. PubMed ID: 30120929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting EFHD2 inhibits interferon-γ signaling and ameliorates non-alcoholic steatohepatitis.
    Fu JT; Liu J; Wu WB; Chen YT; Lu GD; Cao Q; Meng HB; Tong J; Zhu JH; Wang XJ; Liu Y; Zhuang C; Sheng C; Shen FM; Liu X; Wang H; Yu Y; Zhang Y; Liang HY; Zhang JB; Li DJ; Li X; Wang ZB; Wang P
    J Hepatol; 2024 Sep; 81(3):389-403. PubMed ID: 38670321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nuclear receptors and nonalcoholic fatty liver disease.
    Cave MC; Clair HB; Hardesty JE; Falkner KC; Feng W; Clark BJ; Sidey J; Shi H; Aqel BA; McClain CJ; Prough RA
    Biochim Biophys Acta; 2016 Sep; 1859(9):1083-1099. PubMed ID: 26962021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of immune responses in the development of NAFLD-associated liver cancer and prospects for therapeutic modulation.
    Yahoo N; Dudek M; Knolle P; Heikenwälder M
    J Hepatol; 2023 Aug; 79(2):538-551. PubMed ID: 36893854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
    Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
    J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treating inflammation to combat non-alcoholic fatty liver disease.
    Wiering L; Tacke F
    J Endocrinol; 2023 Jan; 256(1):. PubMed ID: 36259984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reprogramming of Hepatic Metabolism and Microenvironment in Nonalcoholic Steatohepatitis.
    Rui L; Lin JD
    Annu Rev Nutr; 2022 Aug; 42():91-113. PubMed ID: 35584814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Roles of the peroxisome proliferator-activated receptors (PPARs) in the pathogenesis of nonalcoholic fatty liver disease (NAFLD).
    Qiu YY; Zhang J; Zeng FY; Zhu YZ
    Pharmacol Res; 2023 Jun; 192():106786. PubMed ID: 37146924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-NASH Drug Development Hitches a Lift on PPAR Agonism.
    Boeckmans J; Natale A; Rombaut M; Buyl K; Rogiers V; De Kock J; Vanhaecke T; M Rodrigues R
    Cells; 2019 Dec; 9(1):. PubMed ID: 31877771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crucial role of T cells in NAFLD-related disease: A review and prospect.
    Mao T; Yang R; Luo Y; He K
    Front Endocrinol (Lausanne); 2022; 13():1051076. PubMed ID: 36457551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapies in non-alcoholic steatohepatitis (NASH).
    Oseini AM; Sanyal AJ
    Liver Int; 2017 Jan; 37 Suppl 1(Suppl 1):97-103. PubMed ID: 28052626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Multifaceted Roles of Macrophages in NAFLD Pathogenesis.
    Vonderlin J; Chavakis T; Sieweke M; Tacke F
    Cell Mol Gastroenterol Hepatol; 2023; 15(6):1311-1324. PubMed ID: 36907380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.
    Kanda T; Goto T; Hirotsu Y; Masuzaki R; Moriyama M; Omata M
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipidomics in pathogenesis, progression and treatment of nonalcoholic steatohepatitis (NASH): Recent advances.
    Musso G; Saba F; Cassader M; Gambino R
    Prog Lipid Res; 2023 Jul; 91():101238. PubMed ID: 37244504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging novel targets for nonalcoholic fatty liver disease treatment: Evidence from recent basic studies.
    Wang GY; Zhang XY; Wang CJ; Guan YF
    World J Gastroenterol; 2023 Jan; 29(1):75-95. PubMed ID: 36683713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 51.